103 / 105
T
reatment
of
advanced
melanoma
– A
changing
landscape
R
ev
A
ssoc
M
ed
B
ras
2017; 63(9):814-823
823
24.
Dummer R, Schadendorf D, Ascierto PA, Fernández AMA, Dutriaux C, Maio
M, et al. Results of NEMO: a phase III trial of binimetinib (BINI) vs
dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. J Clin Oncol.
2016; 34(Suppl):abstr9500). [2016 ASCO Annual Meeting]
25.
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez
A, et al. Imatinib for melanomas harboring mutationally activated or
amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
J Clin Oncol. 2013; 31(26):3182-90.
26. Carvajal RD, Antonescu CR, Wolchock JD, Chapman PB, Roman RA, Teitcher
J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;
305(22):2327-34.
27.
Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, et al.
Phase II trial of imatinib mesylate in patients with metastatic melanoma.
Br J Cancer. 2008; 99(5):734-40.
28. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-
arm trial of imatinib mesylate in patients withmetastatic melanoma harboring
c-KIT mutation or amplification. J Clin Oncol. 2011; 29(21):2904-9.
29.
Hennecke J, Wiley DC. T cell receptor-MHC interactions up close. Cell. 2001;
104(1):1-4.
30. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-
inhibition. Nat Rev Immunol. 2013; 13(4):227-42.
31.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et
al. Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010; 3638):711-23.
32.
Schadendorf D, Hodi FS, Robert C, Weber IS, Margolin K, Hamid O, et al.
Pooled analysis of long-term survival data from Phase II and Phase III trials
of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;
33(17):1889-94.
33. Ascierto PA, Del Vecchio M, Robert C, Mackiewcz A, Chiarion-Sileni V, Arance
Fernandez AM, et al. Overall survival (OS) and safety results from a phase 3
trial of ipilimumab (IPI) at 3mg/kg vs 10mg/kg in patients with metastatic
melanoma (MEL). In: ESMO, 2016, Copenhagen. Annals of Oncology,
Copenhagen, Denmark, Oxford University Press, 2016. Abstr. vi379.
34.
Ribas A, Hamid O, Daud A, Hodi FS, Wolchok J D, Kefford R, et al.
Association of Pembrolizumab with tumor response and survival among
patients with advanced melanoma. JAMA. 2016; 315(15):1600-9.
35. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman
WH, et al. Survival, durable tumor remission, and long-term safety in patients
with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;
32(10):1020-30.
36.
Ribas A, Puzanov I, Dummer R, Scadendorf D, Hamid O, Robert C, et al.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-
refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2
trial. Lancet Oncol. 2015; 16(8):908-18.
37. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al.
Nivolumab versus chemotherapy in patients with advanced melanoma who
progressed after anti-CTLA-4-treatment (CheckMate 037): a randomised,
controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84.
38.
Daud A, Blank CU, Robert C, Puzanov I, Richtig E, Margolin KA, et al.
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi)
for advanced melanoma: efficacy by PD-L1 expression and line of therapy.
J Clin Oncol. 2016; 34(Suppl):abstr9513. [2016 ASCO Annual Meeting]
39.
Schacter J, Ribas A, Ling GV, Arance A, Grob JJ, Mortier L, et al.
Pembrolizumab versus ipilimumab for advanced melanoma: Final overall
survival analysis of KEYNOTE-006. J Clin Oncol. 2016; 34(Suppl):abstr9504.
[2016 ASCO Annual Meeting]
40.
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D,
et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med. 2015; 372(21):2006-17.
41.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al.
Combined Nivolumab and Ipilimumab or monotherapy in untreated
melanoma. N Engl J Med. 2015; 373(1):23-34.
42. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey
CL, et al. Updated results from a phase III trial of nivolumab (NIVO)
combined with ipilimumab (IPI) in treatment-naive patients (pts) with
advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2016;
34(Suppl):abstr9505. [2016 ASCO Annual Meeting]
43.
Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM,
et al. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma:
Results of the KEYNOTE-029 expansion cohort. J Clin Oncol. 34, 2016;
34Suppl):abstr9506. [2016 ASCO Annual Meeting]
44.
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U.
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 2015; 26(Suppl 5):v126-32.
45.
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age.
Nature. 2011; 480(7378):480-9.
46. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney
J, et al. Talimogene Laherparepvec improves durable response rate in patients
with advanced melanoma. J Clin Oncol. 2015; 33(25):2780-8.
47.
Puzanov I, MilhemMM, Minor D, Hamid O, Li A, Chen L, et al. Talimogene
Laherparepvec in combination with ipilimumab in previously untreated, un-
resectable stage IIIB-IV melanoma. J Clin Oncol. 2016; 34(22):2619-26.
48.
Long GV, Dummer R, Ribas A, Puzanov I, VanderWalde A, Hans R, Andtbacka
I, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene
laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage
IIIB-IV melanoma. J Clin Oncol. 2016; 34(Suppl):abstr9568. [2016 ASCO
Annual Meeting].
49.
Hamid O, Patel M, Hodi S, Amaria R, Boasberg P, Sullivan R, et al. Preliminary
clinical safety, tolerability and activity of atezolizumab (anti-PD-L1) combined
with Zelboraf in BRAFv600 metastatic melanoma. Presented at the 12
Congress of the Society for Melanoma Research 2015; November 18-21,
2015; San Francisco, CA. Abstract.
50.
Ribas A, Hodi FS, Lawrence DP, Atkinson V, Starodub A, Carlino MS, et al.
Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib
(T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.
J Clin Oncol. 2016; 34(Suppl):abstr 3014. [2016 ASCO Annual Meeting].